AMIX

Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies

Abstracts highlight potential of Autonomix's transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark.

New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain

THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company's common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.

Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models.

Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care

Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain

Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation

Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications THE WOODLANDS, TX, July 23, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods," further strengthening the Company's intellectual property portfolio supporting its proprietary autonomic nervous system technologies.

Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder.